On Friday, Fulcrum Therapeutics Inc (NASDAQ: FULC) opened lower -9.49% from the last session, before settling in for the closing price of $3.32. Price fluctuations for FULC have ranged from $2.87 to $13.70 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -1.10% annually for the last half of the decade. Company’s average yearly earnings per share was noted 89.15% at the time writing. With a float of $54.18 million, this company’s outstanding shares have now reached $61.92 million.
In an organization with 76 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 77.44%, operating margin of -37.66%, and the pretax margin is -22.15%.
Fulcrum Therapeutics Inc (FULC) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Fulcrum Therapeutics Inc is 15.49%, while institutional ownership is 75.71%. The most recent insider transaction that took place on May 07 ’24, was worth 1,831. In this transaction Principal Accounting Officer of this company sold 236 shares at a rate of $7.76, taking the stock ownership to the 11,571 shares. Before that another transaction happened on Mar 08 ’24, when Company’s Vice President, Finance sold 4,884 for $11.72, making the entire transaction worth $57,219. This insider now owns 11,807 shares in total.
Fulcrum Therapeutics Inc (FULC) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 89.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.40% during the next five years compared to 1.09% growth over the previous five years of trading.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Trading Performance Indicators
Check out the current performance indicators for Fulcrum Therapeutics Inc (FULC). In the past quarter, the stock posted a quick ratio of 18.44. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.31, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach -1.06 in one year’s time.
Technical Analysis of Fulcrum Therapeutics Inc (FULC)
Let’s dig in a bit further. During the last 5-days, its volume was 0.87 million. That was inferior than the volume of 0.99 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 27.37%. Additionally, its Average True Range was 0.26.
During the past 100 days, Fulcrum Therapeutics Inc’s (FULC) raw stochastic average was set at 1.93%, which indicates a significant decrease from 5.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.98% in the past 14 days, which was lower than the 167.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.75, while its 200-day Moving Average is $7.27. However, in the short run, Fulcrum Therapeutics Inc’s stock first resistance to watch stands at $3.22. Second resistance stands at $3.43. The third major resistance level sits at $3.57. If the price goes on to break the first support level at $2.87, it is likely to go to the next support level at $2.74. The third support level lies at $2.52 if the price breaches the second support level.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Key Stats
There are currently 53,939K shares outstanding in the company with a market cap of 146.71 million. Presently, the company’s annual sales total 2,810 K according to its annual income of -97,340 K. Last quarter, the company’s sales amounted to 80,000 K and its income totaled 55,410 K.
